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Cancer during pregnancy is occurring more often than in the past, and it is estimated that cancer 
is diagnosed in approximately 1/1000 pregnancies. A consensus exists that management of these 
patients should prioritize survival of the mother and minimize teratogenic effects to the fetus, 
and utilize a multidisciplinary approach, involving medical oncology, surgical oncology, 
radiation oncology, radiology, and a maternal fetal medicine specialist. In spite of this 
consensus, there is not a standardized approach for treating cancer in women diagnosed during 
pregnancy. Due to the relative infrequency of this situation in the oncologic setting, the aims of 
this study were to determine how comfortable oncologists are discussing pregnancy issues 
related to treatment, specifically termination and fetal risks, to determine what oncologists view 
as their primary responsibilities in the management of a woman diagnosed with cancer during 
pregnancy, and to identify the challenges oncologists face when treating a woman diagnosed 
with cancer during pregnancy. An 18 question survey was developed and distributed to 
oncologists at The Methodist Hospital and the Memorial Hermann Hospital system. The results 
from 53 completed anonymous surveys showed that oncologists who have treated at least one 
patient diagnosed with cancer during pregnancy are significantly more likely to be comfortable 
treating this patient population (p<0.01). Thus, providing care to one patient within this 
population may be sufficient to establish a level of comfort in providing clinic care to a patient 
diagnosed with cancer during pregnancy. Providers appear to recognize that a multidisciplinary 
approach is needed when treating this patient population, though have differing opinions 
regarding whom of these providers has the highest practice responsibility to address pregnancy-
related topics, including termination of pregnancy and risk of teratogenic effects. Additionally, 
many providers acknowledge that barriers exist which create added challenges when treating 
this patient population.  
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Background 
Cancer during pregnancy is occurring more often than in the past, as women are 
delaying childbearing until later in life.  Cancer is diagnosed in approximately 1/1000 
pregnancies, with the most common cancers seen during pregnancy being breast cancer, cervical 
cancer, Hodgkin and Non-Hodgkin lymphoma, leukemias, and melanoma (1).  The National 
Comprehensive Cancer Network (NCCN) published guidelines for treatment of breast cancer 
during pregnancy in 2006 (2). For additional cancers, a consensus exists that management 
should prioritize survival of the mother while minimizing teratogenic effects to the fetus (3); it 
is further suggested that a multidisciplinary approach be used, involving medical, surgical, and  
radiation oncology, radiology, and a maternal fetal medicine specialist (MFM) (4).  In spite of 
this consensus, there is not a standardized approach for treating cancer in patients diagnosed 
during pregnancy. 
 Breast cancer is the most common cancer diagnosed in women, and the most common 
diagnosis during pregnancy.  It is estimated to occur in 1/1500-1/4000 pregnancies, and 
approximately 10% of breast cancer patients younger than age 40 are diagnosed during 
pregnancy or up to one year postpartum (5, 6, 7).  Several factors delay diagnosis, including 
physiological changes in the breast during pregnancy, making the diagnosis of advanced stage 
disease a common occurrence (8, 9).  Breast surgery is safe during pregnancy, but a general 
agreement exists to postpone radiation therapy and endocrine therapy until the postpartum 
period, as both have been associated with a high risk of fetal toxicity (6, 10, 11).  The young age 
at which pregnant women are diagnosed with breast cancer puts them at an increased likelihood 
of carrying a BRCA1 or BRCA2 mutation.  In these instances, genetic testing for hereditary 
breast and ovarian cancer syndrome should be considered (12). 
 Additional cancers more commonly seen in pregnancy include cervical cancer, 
hematologic malignancies, leukemias, and melanoma. These diagnoses occur during pregnancy 
at rates from 1/6000 to 1/100000, with lymphomas being the most common, and melanoma 
being the most likely malignancy to metastasize to the placenta and fetus (3, 13, 14, 15, 16, 17, 
18, 19, 20, 21, 22).  Treatment approaches for each of these cancers during pregnancy should be 
individualized depending on disease staging, gestational age, and treatment options. 
When faced with a cancer diagnosis during pregnancy, a multidisciplinary approach is 
recommended, which may include oncologic specialties, surgery, and high risk obstetrics (9).  
Cancer management is associated with potential teratogenic effects, including clinical use of 
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supportive agents, ionizing radiation exposure, and infection-related fever (23, 24).  Risks of 
fetal structural defects as a result of chemotherapy administration are greatest in the first 
trimester, and radiation therapy should be delayed until after delivery.  Given the limited data 
regarding single-agent exposures, broad comparisons cannot be made to the risks associated 
with combination therapies utilized during cancer treatment (24).  Chemotherapy treatment is 
thought to pose fewer risks when administered in the second and third trimesters, though 
exposure during this time has been associated with transient neonatal disorders.  While these 
tend to resolve, the greatest concern associated with second and third trimester exposures is 
harmful effects on fetal brain development (7).   
While some information is available regarding potential approaches to cancer 
management during pregnancy, outcome information is largely based on small numbers of case 
series. Additionally, pregnant women are excluded from nearly all cancer trials and drug trials, 
further preventing the establishment of clinical evidence to guide recommendations (11). In 
current practice, oncologists rarely recommend termination of pregnancy, as the historical 
practice of termination of pregnancy secondary to cancer has not been associated with improved 
survival (11, 25, 26, 27).  The diagnosis of an aggressive or advanced disease may be an 
exception, as immediate treatment is needed to avoid patient mortality (11, 28, 29). 
Consideration of whether to terminate pregnancy following a cancer diagnosis should be made 
in the context of disease, agents and drugs to be used, probability of achieving a cure, and 
patient desires (30). 
 As the incidence of cancer during pregnancy continues to rise, clinicians will 
increasingly face challenges in managing cancer during pregnancy, particularly in developing a 
treatment plan to maximize maternal benefits and minimize the risk of adverse pregnancy 
outcomes (23).  Studies in the past have tried to characterize approaches towards cancer during 
pregnancy, but information remains limited.  Additionally, information regarding the scope of 
practice of oncologists in caring for a pregnant patient is scarce. A European study aimed to 
evaluate provider opinions and knowledge surrounding the treatment possibilities for patients 
with cancer in pregnancy and found that providers are uncertain regarding the timing and 
approach towards treating cancer during pregnancy (31).  In light of deficiencies in the amount 
of information surrounding this topic in the oncologic setting, the goal of the current study was 
to gain more insight into the perceived views of pregnancy management and challenges faced 
by oncologists when treating women diagnosed with cancer during pregnancy. 
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Materials and Methods 
A four-page survey was designed with 18 questions on oncologists’ opinions and 
perceptions in the treatment of cancer during pregnancy (Appendix 1). The first section of the 
survey assessed oncologists’ comfort level and experience with pregnant patients. The second 
half of the survey inquired about the practice responsibilities and challenges of oncologists 
when treating pregnant patients. Demographics, practice type, and self-reported number of 
pregnant cancer patients seen were also examined. Human subject research approval was 
obtained for the Methodist Hospital, the Memorial Hermann Health System, and the University 
of Texas Health Science Center by the Institutional Review Board at each site.  Both online and 
paper survey data were collected beginning in October 2013, and ending in March 2014. 
SurveyMonkey (http://www.surveymonkey.com) was utilized for email survey distribution and 
data collection. Additionally, surveys were distributed during tumor board meetings at the 
Houston Methodist Hospital system and the Memorial Hermann Health System.  Participants 
were not required to answer all questions; therefore, some answers have missing values.  
 Statistical analysis software, Stata (v.13.0, College Station, TX), was used to perform 
standard descriptive analysis of categorical variables, including number of respondents and 
percentages across categories.  Kruskal-Wallis tests were used to compare differences in 
comfort level by various predictor factors. Univariable and multivariable logistic regression 
analyses were used to identify significant associations between respondents’ demographic 
information, reported comfort level, perceived practice responsibilities, and barriers identified 
which create challenges when treating this patient population. Statistical significance was 
assumed at confidence intervals that did not include the null value (1.0) or at a p-value <0.05. 
Results 
Demographic Information 
A total of 62 surveys were submitted: 5 surveys (8.1%) were excluded because all questions 
regarding cancer during pregnancy were unanswered, with 4 (6.4%) excluded because the 
survey was completed by an individual ineligible to participate in the study based on practice 
area. This left a final sample size of 53 (85.5%) for analysis. Table 1 shows the demographic 
data of the respondents. Most were medical oncologists (55.8%), with the remaining 
respondents divided between radiation, surgical, and gynecologic oncology. Approximately 
83% of respondents had treated at least one patient diagnosed with cancer during pregnancy 
during their career, with 17% having no experience with this patient population. 
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Table 1. Participant Demographics 
Institution (n=53) n % 
Methodist 20 37.7 
UT Memorial Hermann Hospital (UTMHH) 33 62.3 
Survey Format (n=53) n % 
Online 24 45.3 
Paper 29 54.7 
Gender (n=53) n % 
Male 32 60.4 
Female 21 39.6 
Residency Completed (year) (n=53) n % 
<1985 12 22.6 
1985-1994 11 20.8 
1995-2005 15 28.3 
>2005 15 28.3 
Years of Experience (n=53) n % 
0-5 years 16 30.2 
6-10 years 7 13.2 
11-15 years 7 13.2 
16-20 years 2 3.8 
>20 years 21 39.6 
Practice Area (n=52) n % 
Medical Oncology 29 55.8 
Surgical Oncology 7 13.4 
Radiation Oncology 8 15.4 
Gynecologic Oncology 8 15.4 
Subspecialty (n=53) n % 
Breast 16 30.2 
GI 4 7.5 
Hematology 4 7.5 
Endocrine 0 0.0 
Other 4 7.5 
Not Applicable 25 47.2 
Practice Setting (n=53) n % 
Academic Hospital 25 47.2 
Private Practice 24 45.3 
Community Hospital 6 11.3 
Cancer Center 4 7.5 
Total Number of Pregnant Patients Seen 
During Career Span (n=53) 
n % 
None 9 17.0 
1-5 29 54.7 
>5 15 28.3 
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Oncologist Comfort Level 
The comfort level of oncologists in treating patients diagnosed with cancer during pregnancy 
was assessed using a 5-point Likert scale. Approximately 60% of respondents stated they were 
comfortable/very comfortable in treating this patient population, with remaining respondents 
being divided between feeling uncertain and uncomfortable/very uncomfortable. Comfort level 
in discussing effects of treatment on pregnancy management and/or the fetus, and in discussing 
prognosis, pregnancy options, and future considerations for the patient (Table 2) were assessed.  
Overall, participants displayed consistency in their degree of comfort when discussing various 
pregnancy-related topics with patients in regards to cancer management. At least 50% of 
participants reported being comfortable/very comfortable in discussing pregnancy related topics, 
with the discussion of long-term risks to the child being the exception (40%).  Participants were 
comfortable/very comfortable (52%) in the discussion of termination of pregnancy, with 17% 
feeling uncertain, and 30% feeling uncomfortable/very uncomfortable. 
 
Table 2. Responses to the question pertaining to comfort level in discussing the effects of 
treatment 
Answer Options 
Very 
Uncomfortable 
(%) 
Uncomfortable 
(%) 
Uncertain 
(%) 
Comfortable 
(%) 
Very 
Comfortable 
(%) 
Risks of 
Chemotherapy 
9 (17.0) 5 (9.4) 6 (11.3) 19 (35.8) 14 (26.4) 
Risk of 
Teratogenic 
Effects 
7 (13.2) 7 (13.2) 6 (11.3) 19 (35.8) 14 (26.4) 
Risks of Surgery 7 (13.2) 8 (15.1) 7 (13.2) 20 (37.7) 11 (20.8) 
Risk of 
treatment-
related Birth 
Defects 
8 (15.1) 7 (13.2) 9 (17.0) 16 (30.2) 13 (24.5) 
Risk of Delivery 
Complications 
9 (17.0) 6 (11.3) 9 (17.0) 20(37.7) 9 (17.0) 
Risks of 
Radiation 
Therapy 
8 (15.1) 6 (11.3) 12 (22.6) 14 (26.4) 13 (24.5) 
Long-term Risks 
to the child 
8 (15.1) 7 (13.2) 16 (30.2) 11 (20.8) 11 (20.8) 
Risk of 
Transient fetal 
conditions 
7 (13.2) 7 (13.2) 18 (34.0) 9 (17.0) 12 (22.6) 
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Table 3. Responses to the question pertaining to comfort level in discussing prognosis, 
pregnancy options, and future considerations 
Answer Options 
Very  
Uncomfortable 
(%) 
Uncomfortable 
(%) 
Uncertain 
(%) 
Comfortable 
(%) 
Very  
Comfortable 
(%) 
Prognosis and 
effect of 
pregnancy on 
prognosis 
7 (13.2) 4 (7.5) 9 (17.0) 18 (34.0) 15 (28.3) 
Timing of 
Delivery with 
respect to the 
treatment plan 
7 (13.2) 7 (13.2) 8 (15.1) 19 (35.8) 12 (22.6) 
Implications for 
Future Fertility 
6 (11.3) 5 (9.4) 11 (20.8) 15 (28.3) 16 (30.2) 
Risk of cancer 
Metastasis 
8 (15.1) 5 (9.4) 10 (18.9) 17 (32.1) 13 (24.5) 
Implications for 
Breast Feeding 
5 (9.4) 6 (11.3) 13 (24.5) 16 (30.2) 13 (24.5) 
Termination of 
pregnancy 
7 (13.2) 9 (17.0) 9 (17.0) 16 (30.2) 12 (22.6) 
 
Oncologist Practice Responsibilities 
The practice responsibilities of oncologists in managing women diagnosed with cancer during 
pregnancy were examined. Participants were questioned on whom they believe should be 
involved in the care of a patient diagnosed with cancer during pregnancy. They were 
additionally asked who has the highest responsibility to discuss termination of pregnancy and 
teratogenic risks to the fetus with the patient, and to rank sources they would refer to for 
information pertaining to teratogenic effects of cancer treatments during pregnancy (Table 4).  
MFM’s and medical oncologists ranked highly across all questioning. Genetic counselors and 
surgical oncologists were ranked as having low responsibility to discuss termination of 
pregnancy and teratogenic risks to the fetus.  In examining sources of reference for information 
pertaining to teratogenic effects of cancer treatment, MFM’s ranked highest, with Ob/Gyns and 
a search engine such as PubMed ranking lowest as sources of information participants would 
reference. 
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Table 4. Patient management and practice responsibility 
 
Health Care Provider 
Responsibility Rank 
High (%) Mid (%) Low (%) 
Responsibility to 
discuss termination 
of pregnancy as a 
treatment option  
Medical Oncologist n=44  30 (68.2) 10 (22.7) 4 (9.1) 
MFM n=40  27 (67.5) 11 (27.5) 2 (5.0) 
Ob/Gyn n=40  26 (65.0) 11 (27.5) 3 (7.5) 
Genetic Counselor n=35  5 (14.3) 13 (37.1) 17 (48.6) 
Surgical Oncologist n=35  1 (2.9) 23 (65.7) 11 (31.4) 
Other n=1  1 (100.0) 0 (0.0) 0 (0.0) 
 
Health Care Provider 
Responsibility Rank 
High (%) Mid (%) Low (%) 
Responsibility to 
discuss the 
teratogenic risks to 
the fetus related to 
cancer treatment 
options 
Medical Oncologist n=45  36 (80%) 7 (15.6) 2 (4.4) 
MFM n=40  23 (57.5) 12 (30.0) 5 (12.5) 
Ob/Gyn n=36  16 (44.4) 12 (33.3) 8 (22.2) 
Radiation Oncologist n=36  9 (25.0) 22 (61.1) 5 (13.9) 
Genetic Counselor n=36  6 (16.7) 10 (27.8) 20 (55.6) 
Surgical Oncologist n=35  4 (11.4) 8 (22.9) 23 (65.7) 
Other n=3  3 (100.0) 0 (0.0) 0 (0.0) 
 
Health Care Provider 
Reference Rank 
High (%) Mid (%) Low (%) 
Sources of reference 
for information 
pertaining to 
teratogenic effects of 
cancer treatments 
during pregnancy 
MFM n=42 31 (73.8) 11 (26.2) 0 (0.0) 
Oncologist Colleague n=45 28 (62.2) 9 (20.0) 8 (17.8) 
Genetic Counselor n=36 11  (30.5) 14 (38.9) 11 (30.5) 
Teratogen Helpline n=35 11 (31.4) 13 (37.1) 11 (31.4) 
Ob/Gyn n=32 8 (25.0) 17 (53.1) 7 (21.9) 
PubMed n=32 7 (21.9) 10 (31.2) 15 (46.9) 
 
Challenges 
Participants were lastly asked to identify barriers which they felt created challenges when 
treating a patient diagnosed with cancer during pregnancy (Table 5). Approximately 20% of 
participants wrote-in additional barriers which they felt create challenges (Appendix 2).  
Approximately 80% of all respondents felt that there was at least one barrier, with most 
reporting more than one barrier. Of these, 83% had experience treating at least one pregnant 
patient in their career. Of those reporting no barriers, only one respondent (16%) had no 
experience treating pregnant patients in their career. Those who felt there were other challenges 
were primarily comfortable in treating patients diagnosed during pregnancy. 
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Table 5. Barriers which create challenges in managing patients diagnosed with cancer during 
pregnancy 
Answer Options Agree (%) 
Disagree 
(%) 
Lack of prevalence of this patient population creates barriers 34 (64.2) 19 (35.8) 
Knowledge of safe treatment options creates barriers 31 (58.5) 22 (41.5) 
Lack of standardization of care creates barriers 29 (54.7) 24 (45.3) 
Amount of information available for reference creates barriers 28 (52.8) 25 (47.2) 
There are no barriers 11 (20.8) 42 (79.2) 
Other challenges create barriers 11 (20.8) 42 (79.2) 
 
Statistically significant differences in comfort level were observed separately for gender, 
survey format, and institution; however, multivariable ordinal logistic regression analysis 
demonstrated that when controlling for experience with the patient population, the differences 
seen between institutions was found to be non-significant (p=0.072). Additionally, when 
controlling for the institution demographic, the differences seen between gender (p=0.665) and 
survey format (p=0.230) were found to be non-significant.  
Associations between participant experience with patients diagnosed during pregnancy 
and comfort level in treating pregnant patients was assessed: participants who had treated at 
least one patient diagnosed during pregnancy were significantly more likely to feel comfortable 
when treating pregnant patients (p<0.01) (Figure 1).  
 
Figure 1. Reported comfort level in treating a patient diagnosed during pregnancy based on 
experience with this patient population (p<0.01) 
0% 
20% 
40% 
60% 
80% 
100% 
Very 
Uncomfortable 
Uncomfortable Uncertain Comfortable Very 
Comfortable 
Pregnant  
Patients 
Treated  
over Span  
of Career 
Comfort Level 
>5 
1-5 
None 
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The comfort level of oncologists in discussing pregnancy-related topics associated with 
cancer treatment was also assessed. Pair-wise correlation analysis demonstrated that the topics 
assessed in Tables 2 and 3 were highly correlated with one another (at least 60%), with 
approximately 55% demonstrating greater than 80% correlation. Thus, if a participant was 
comfortable with one pregnancy-related topic, they were significantly more likely to be 
comfortable with all topics (p<0.001).  Overall, participants reported they are comfortable 
treating patients diagnosed with cancer during pregnancy and discussing pregnancy topics 
related to cancer treatment.  
The oncologic sub-specialty of participants influenced comfort levels, with surgical and 
radiation oncologists significantly more likely to be uncomfortable with certain topics when 
compared to medical and gynecologic oncologists. These topics included discussing risks of 
surgery (p<0.01), risks of chemotherapy (p<0.01), risk of treatment-related birth defects 
(p<0.05), risk of transient neonatal conditions (p<0.05), risk of delivery complications (p<0.05), 
risk of cancer metastasis (p<0.05), termination of pregnancy (p<0.05), timing of delivery with 
respect to the treatment plan (p<0.01), and implications for breast feeding (p<0.05). Participants 
who were uncomfortable discussing the following were significantly more likely to rank a 
genetic counselor as being a high reference for information pertaining to teratogenic effects of 
cancer treatments (p<0.05): risks of surgery, risk of treatment-related birth defects, risk of 
transient neonatal conditions, long-term risks to the child, prognosis and the effect of pregnancy 
on prognosis, timing of delivery with respect to the treatment plan, risk of cancer metastasis, 
and implications for breast feeding.  Oncologist colleagues and MFM’s were consistently 
ranked highly for reference regarding teratogens; however this was not found to be statistically 
significant when compared with overall comfort in treating, or when examined for comfort level 
across all pregnancy-related discussion topics. 
Participants who felt uncomfortable discussing pregnancy-related topics were 
significantly more likely to rank Ob/Gyns as having high responsibility to discuss termination of 
pregnancy (p<0.05).  However, participants who practice gynecologic oncology were 
significantly more likely to think an Ob/Gyn does not need to be involved in the care of a 
patient diagnosed with cancer during pregnancy (p<0.01). Participants who felt uncomfortable 
discussing risks of teratogenic effects and risk of metastasis were significantly more likely to 
rank medical oncologists as having high responsibility to discuss teratogenic risks to the fetus 
(p<0.05).  Lastly, those who ranked genetic counselors as having high responsibility to discuss 
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teratogens were significantly more likely to be uncomfortable treating patients diagnosed with 
cancer during pregnancy (p<0.01). 
Those participants who that felt there were no barriers when treating this patient 
population were examined for comfort level when treating a patient diagnosed with cancer 
during pregnancy, but this was not found to be statistically significant (p>0.1).  
Discussion 
The goal of this study was to identify the perceived views of pregnancy management and 
challenges faced by oncologists when treating women diagnosed with cancer during pregnancy.  
Few studies have specifically examined oncologist comfort level, though one demonstrated 
oncologist discomfort in utilization of psychosocial talk in comparison with nurses and 
physician assistants (32). To the best of current knowledge, this is the first study to assess the 
comfort level of oncologists in regards to cancer diagnosis during pregnancy. Given that 1/1000 
pregnancies are diagnosed with cancer, it was thought oncologists would be uncomfortable 
discussing pregnancy recommendations. This study found the majority of participants had 
treated at least one patient diagnosed with cancer during pregnancy (83%), and participants with 
limited experience (1-5 patients) reported a greater level of comfort treating these patients 
compared to those with no experience (0 patients). Those who had treated more than 5 patients 
diagnosed with cancer during pregnancy were significantly more likely to feel comfortable 
when treating this patient population compared to those with less experience (p<0.01). While 
the sample population was skewed due to the tertiary care environment of the institutions 
involved in this study, it appears that treating a few patients diagnosed with cancer during 
pregnancy may be sufficient for a provider to feel comfortable treating this patient population 
overall.  
Comfort level in discussing termination of pregnancy was the only topic assessed that 
did not have a significant association with comfort level overall in treating this patient 
population (p=0.08). Thus, provider comfort level in treating a patient diagnosed with cancer 
during pregnancy cannot be used as a predictor for comfort in discussing termination of 
pregnancy. Because participants tended to be less comfortable discussing termination of 
pregnancy, this may explain the high ranking of MFM’s in regards to practice responsibility to 
discuss termination. However, many other factors influence comfort level in discussing 
termination aside from training and whether it traditionally falls within a provider’s scope of 
practice. For instance, overall personal beliefs and feelings are likely to influence comfort level. 
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The findings of this study suggest medical oncologists and MFM’s have a significant 
role in the management of this patient population. Genetic counselors were consistently ranked 
as having low responsibility to discuss pregnancy-related topics with patients. This study did not 
assess awareness of the practice competencies of genetic counselors, nor did it assess whether 
participants routinely work with a genetic counselor. Additionally, the distinction between 
different genetic counseling specialties was not taken into account.  Participant responses may 
reflect that they feel a cancer genetic counselor has low responsibility to discuss these topics, 
but they may feel a prenatal genetic counselor has higher responsibility. 
While the diagnosis of cancer during pregnancy more prevalent now than in the past, 
particularly as women continue to delay childbearing, barriers which create challenges when 
treating this patient population continue to exist. NCCN guidelines for the clinical management 
of women diagnosed with breast cancer during pregnancy were published in 2006 (2), but 
similar guidelines for additional cancers have not yet been established. Participants identified 
the lack of standardization of care as a barrier which creates challenges in the management of 
pregnant patients. Thus, the creation of guidelines for the treatment of other cancers during 
pregnancy may decrease the barriers perceived by providers, and potentially contribute to 
overall comfort when treating this patient population. 
There were limitations to this study, first in the number of providers included in the 
study. Surveying a wider variety and larger number of providers may provide further insights to 
the clinical management of women diagnosed with cancer during pregnancy.  The two 
institutions utilized in the study are in a tertiary care environment, with participants being more 
likely to have experience with pregnant patients than oncologists in the general setting.  
Therefore, it may be difficult to generalize the findings of this study across the field of 
oncology.  Additionally, a large proportion of study participants subspecialize in the treatment 
of breast cancer, the only cancer for which standardized guidelines for treatment exist, creating 
a potential respondent bias. 
In spite of limitations, the findings of this study provide a platform for future studies, 
which may include assessing provider knowledge and gathering opinions in regards to treatment 
approach, and in assessing the involvement of genetic counseling and genetic testing. Given the 
high ranking of MFM’s in regards to practice responsibilities, the survey in this study could be 
administered to MFM’s to assess whether trends in MFM comfort level reflect those 
demonstrated by oncologists. In addition, a study examining the knowledge of providers in 
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regards to the scope of practice of genetic counselors may provide additional insights regarding 
the importance of genetics when considering a cancer diagnosis during pregnancy. 
In conclusion, the findings of this study suggest that experience with women diagnosed 
with cancer during pregnancy is directly related to comfort level in treating this patient 
population; providing care to a few pregnant patients may be sufficient to establish a level of 
comfort in an oncologist when treating pregnant patients. Oncologists recognize that a 
multidisciplinary approach is needed when treating this patient population, though have 
differing opinions regarding whom of these providers has the highest practice responsibility to 
address pregnancy-related topics. Additionally, comfort level and experience aside, oncologists 
acknowledge that barriers exist which create challenges when treating pregnant patients.  
Minimization of these barriers may contribute towards further increasing comfort level when 
treating a woman diagnosed with cancer during pregnancy. 
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Appendix 
Appendix 1. Study Survey 
Part I (Demographics) 
1) What is your gender? 
 Male 
 Female 
 
2) What year did you complete your primary residency? 
_________ (year) 
 
3) What year did you complete your fellowship and/or sub-specialty training?  
Select all that apply: 
 Fellowship: _________(year) 
 Sub-specialty: _________ (year) 
 Not Applicable 
 
4) How many years have you been in practice?  
Please choose one: 
 0-5 years 
 6-10 years 
 11-15 years 
 16-20 years 
 >20 years 
 
5) Which of the following best describes your area of practice?  
Please choose one: 
 Medical Oncology 
 Surgical Oncology  
 Radiation Oncology 
 Gynecologic Oncology 
 
6) Which of the following best describes your sub-specialty?  
Please choose one: 
 Breast 
 GI 
 Hematology 
 Endocrine 
 Other:____________________________ 
 Not Applicable 
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7) What is your primary practice setting?  
Please select all that apply: 
 Academic Hospital 
 Private Practice 
 Community Hospital 
 Cancer Center 
 Other: ___________________________ 
 
8) On average, how many new patients in each setting below do you see each week? 
Inpatient: ____________ (number per week) 
Outpatient: __________ (number per week) 
 
Part II (comfort level/experience) 
1) In the span of your career, how many patients have you treated who were undergoing active 
treatment for cancer during pregnancy?  
Please choose one: 
 None 
 1-5 
 6-10 
 11-15 
 >15 Please specify approximately how many: ______ 
 
2) How comfortable do you feel treating a patient diagnosed with cancer during pregnancy? 
             
Very  Uncomfortable (2)      Uncertain (3)      Comfortable (4)      Very  
Uncomfortable (1) Comfortable (5) 
 
3) How comfortable would you feel discussing the following with a patient diagnosed with 
any cancer during pregnancy? Please indicate your answer choice by marking the 
appropriate column below: 
1= Very Uncomfortable; 2=Uncomfortable; 3=Uncertain; 4=Comfortable; 5=Very Comfortable 
Discussing Effects of Treatment 1 2 3 4 5 
Safety and fetal risks of surgery during pregnancy.      
Safety and fetal risks of radiation therapy administration during pregnancy.      
Safety and fetal risk of chemotherapy administration during pregnancy.      
Risk of teratogenic effects from cancer treatment during pregnancy.      
Risk of birth defects related to treatment.      
Risk of transient fetal conditions related to treatment.      
Long-term risk to the child following treatment during pregnancy.      
Risk of delivery complications related to cancer treatment.      
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4) How comfortable would you feel discussing the following with a patient diagnosed with 
any cancer during pregnancy? Please indicate your answer choice by marking the 
appropriate column below: 
1= Very Uncomfortable; 2=Uncomfortable; 3=Uncertain; 4=Comfortable; 5=Very Comfortable 
Discussing Prognosis, Pregnancy Options, and Future Considerations 1 2 3 4 5 
Prognosis and whether continuation of pregnancy affects the prognosis.      
Risk of cancer metastasis to the fetus and/or placenta.      
Discussing termination of pregnancy.      
How timing of delivery fits into the treatment plan.      
Implications for breast feeding.      
Implications for future fertility.      
 
 
Please respond to the remainder of the survey according to one of the 
following: 
I do not have experience treating a patient diagnosed with cancer during pregnancy.  The 
following reflects how I think I would approach this type of case. 
 
OR 
 
I do have experience treating a patient diagnosed with cancer during pregnancy.  The following 
reflects how I approach this type of case. 
 
 
Part III (practice responsibilities/challenges) 
1) Do you agree or disagree with the following statements? Please indicate your answer 
choice by marking the appropriate column below. 
 
 Agree Disagree 
Your management of a patient would change if she was pregnant at the time 
of diagnosis. 
  
It is one of your practice responsibilities to address pregnancy management 
with patients diagnosed with cancer during pregnancy. 
  
It is one of your practice responsibilities to make appropriate referrals for 
pregnancy management during cancer treatment. 
  
You know which specialists should be following your patient while she is 
being treated during pregnancy, and would feel comfortable making 
those referrals. 
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2) Who do you think should be involved in the care of a patient diagnosed with cancer during 
pregnancy?  
Please select all that apply:   
 Medical Oncology 
 Surgical Oncology 
 Radiation Oncology 
 OB/GYN 
 MFM 
 Genetic Counselor 
 Other: ___________________________________ 
 Not sure 
 
3) Please rank the following accordingly: Who do you feel has the primary responsibility of 
discussing termination of pregnancy as a treatment option with the patient? 
1=highest responsibility; 6 = lowest responsibility 
_______ Medical Oncologist 
_______ Surgical Oncologist 
_______ OB/GYN 
_______ MFM 
_______ Genetic Counselor 
_______ Other: _____________________________________ 
 
4) Please rank the following accordingly:  Who do you feel has the primary responsibility of 
discussing the teratogenic risks to the fetus related to cancer treatment options? 
1=highest responsibility; 7 = lowest responsibility 
_______ Medical Oncologist 
_______ Surgical Oncologist 
_______ Radiation Oncologist 
_______ OB/GYN 
_______ MFM 
_______ Genetic Counselor 
_______ Other: _____________________________________ 
 
5) Please rank the following accordingly: Who/What would you refer to for information 
pertaining to teratogenic effects of cancer treatments during pregnancy, regardless of type of 
treatment? 
1=refer to first; 2=refer to second; 3=refer to third, etc. 
_______ Oncologist Colleague 
_______ MFM 
_______ Ob/Gyn 
_______ Genetic Counselor 
_______ PubMed 
_______ Teratogen helpline/Teratogen information service 
_______ Other: _____________________________________ 
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6) What barriers do you feel create challenges when treating a patient diagnosed with cancer 
during pregnancy? Please mark all that apply: 
 Amount of information available for reference 
 Knowledge of safe treatment options 
 Lack of prevalence of this patient population 
 Lack of standardization of care for this patient population 
 I do not feel that there are any barriers 
 Other, please describe: 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
____________________________________________ 
 
 
 
You have reached the end of the survey. Thank you for your time. 
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Appendix 2. Responses to part III, question 6 of the survey: Other barriers identified that create 
challenges when treating a patient diagnosed with cancer during pregnancy: 
 Discussion of termination of pregnancy as an option 
 No experience; refer to tertiary center 
 Fear of litigation 
 The obvious emotional component AND the stage of the patient, whether curable or 
whether already metastatic 
 Pregnancy and cancer is a very difficult subject especially when radiation therapy had 
potentially devastating effects to a developing fetus. I also find people’s religious views 
have a great barrier when decision making. Also the current political climate regarding 
abortion makes it difficult. 
 A team effort is needed  Although the above questions asked for a rank order--I believe 
the decision should be made with all team members mentioned above being involved  
Just the medical oncologist alone or MFM alone will not be able to make the right 
decision  Each team member has a different expertise and different information to offer 
that can be utilized in decision making  MFM and OBGYN and genetic counselor should 
be actively involved in decision making along with the various oncology colleagues  The 
clinical pharmacist plays a very vital role here and needs to be involved in the decision 
making  Reproductive Endocrinology can be another valuable team member to be 
involved here who can help address current as well as future issues, 
 Historical reports about poor prognosis associated with pregnancy and cancer 
 We routinely perform procedures with patients who are pregnant with and without 
cancer. We modify our procedures by using different medication for sedation to 
minimize radiation use, particularly in the first and second trimesters 
 I think that the best data for management of breast cancer is out of MDACC in 
pregnancy; otherwise, data is scarce. However we do have the experience which is in 
fact well published. 
 Concern for being sued if the fetus has any adverse effects. 
 Rare. 
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